Literature DB >> 12177000

PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription.

Tamotsu Nishida1, Hideyo Yasuda.   

Abstract

The androgen receptor (AR) has been shown to be modified by SUMO-1, a ubiquitin-like protein. Recently we showed that PIAS family proteins function as SUMO-E3 ligases. Here we provide evidence that PIAS1 and PIASxalpha act as specific SUMO-E3 ligases for the AR. PIAS1 and PIASxalpha but not PIAS3 or PIASxbeta enhanced the sumoylation of AR in intact cells and in vitro. PIAS1 and PIASxalpha bound Ubc9, the E2 enzyme for SUMO-1, in a RING finger-like domain-dependent manner. Consistent with previous studies (Kahyo, T., Nishida, T., and Yasuda, H. (2001) Mol. Cell 8, 713-718), the RING finger-like domain of the SUMO-E3 was required for ligase activity. The binding of a ligand, e.g. testosterone, to the AR was required for the sumoylation of AR in intact cells. Although AR-dependent transcription was enhanced by PIAS proteins without sumoylation of the receptor, PIAS1 and PIASxalpha repressed AR-dependent transcription in a manner dependent on the ectopic expression of SUMO-1 and their RING finger-like domain. Furthermore, the sumoylation sites of the AR were necessary for the full repressive effect on AR-dependent transactivation, indicating that the sumoylation of AR was crucial for the repression of transactivation of the AR. Thus, PIAS1 and PIASxalpha modulate the AR-dependent transactivation, which, at least in part, can be attributed to their SUMO-E3 activity toward AR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12177000     DOI: 10.1074/jbc.M206741200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  68 in total

Review 1.  Modification with SUMO. A role in transcriptional regulation.

Authors:  Alexis Verger; José Perdomo; Merlin Crossley
Journal:  EMBO Rep       Date:  2003-02       Impact factor: 8.807

2.  MST1 is a multifunctional caspase-independent inhibitor of androgenic signaling.

Authors:  Bekir Cinar; Filiz Kisaayak Collak; Delia Lopez; Seckin Akgul; Nishit K Mukhopadhyay; Murat Kilicarslan; Daniel G Gioeli; Michael R Freeman
Journal:  Cancer Res       Date:  2011-04-21       Impact factor: 12.701

Review 3.  CHD chromatin remodelers and the transcription cycle.

Authors:  Magdalena Murawska; Alexander Brehm
Journal:  Transcription       Date:  2011-11-01

4.  Nse2, a component of the Smc5-6 complex, is a SUMO ligase required for the response to DNA damage.

Authors:  Emily A Andrews; Jan Palecek; John Sergeant; Elaine Taylor; Alan R Lehmann; Felicity Z Watts
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

5.  A small conserved surface in SUMO is the critical structural determinant of its transcriptional inhibitory properties.

Authors:  Sergey Chupreta; Sam Holmstrom; Lalitha Subramanian; Jorge A Iñiguez-Lluhí
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

Review 6.  Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations.

Authors:  Derek N Lavery; Iain J McEwan
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

7.  SUMO modification enhances p66-mediated transcriptional repression of the Mi-2/NuRD complex.

Authors:  Zihua Gong; Marc Brackertz; Rainer Renkawitz
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

Review 8.  Protein sumoylation in brain development, neuronal morphology and spinogenesis.

Authors:  Carole Gwizdek; Frédéric Cassé; Stéphane Martin
Journal:  Neuromolecular Med       Date:  2013-08-02       Impact factor: 3.843

9.  Identification of a novel role of ZMIZ2 protein in regulating the activity of the Wnt/β-catenin signaling pathway.

Authors:  Suk Hyung Lee; Chunfang Zhu; Yue Peng; Daniel T Johnson; Lynn Lehmann; Zijie Sun
Journal:  J Biol Chem       Date:  2013-10-30       Impact factor: 5.157

10.  PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts.

Authors:  Tomohiro Hikata; Hironari Takaishi; Jiro Takito; Akihiro Hakozaki; Mitsuru Furukawa; Shinichi Uchikawa; Tokuhiro Kimura; Yasunori Okada; Masahito Matsumoto; Akihiko Yoshimura; Riko Nishimura; Sakamuri V Reddy; Hiroshi Asahara; Yoshiaki Toyama
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.